Stefan van den Eijnde
Direttore/Membro del Consiglio presso Dutch Vaccines Group
Profilo
Stefan van den Eijnde is Director of Business Development for MUbio Products BV.
He co-founded NovoVacs BV in 2002.
Dr. van den Eijnde received a Master's degree in Biomedical Sciences from the University of Leiden in 1992 and a PhD in 1999.
Posizioni attive di Stefan van den Eijnde
| Società | Posizione | Inizio |
|---|---|---|
| Dutch Vaccines Group | Direttore/Membro del Consiglio | 01/09/2009 |
| LifetecZONe | Direttore/Membro del Consiglio | 17/05/2010 |
Precedenti posizioni note di Stefan van den Eijnde
| Società | Posizione | Fine |
|---|---|---|
MUbio Holding BV
 MUbio Holding BV BiotechnologyHealth Technology MUbio Products B.V. (MUbio) is a privately owned Dutch biotech company, founded in 2000 by Dr. R. Vleugels and Prof. Dr. F. Ramaekers. The company originated as a spin out from the Department of Molecular Cell Biology of the Maastricht University. MUbio produces high quality reagents and bioassays for cell biology and biomedical research. MUbio's product portfolio includes an increasing number of well-characterized antibodies for oncology research, produced in an ISO certified laboratory. MUbio’s partnered and proprietary R&D projects focus on the identification and validation of cancer biomarkers, development of lung cancer diagnostic kits & research and development of a lung cancer vaccine. | Corporate Officer/Principal | 05/06/2013 |
| Maastricht University | Direttore Tecnico/Scientifico/R&S | - |
| NovoVacs BV | Fondatore | - |
Formazione di Stefan van den Eijnde
| University of Leiden | Graduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 4 |
|---|---|
MUbio Holding BV
MUbio Holding BV BiotechnologyHealth Technology MUbio Products B.V. (MUbio) is a privately owned Dutch biotech company, founded in 2000 by Dr. R. Vleugels and Prof. Dr. F. Ramaekers. The company originated as a spin out from the Department of Molecular Cell Biology of the Maastricht University. MUbio produces high quality reagents and bioassays for cell biology and biomedical research. MUbio's product portfolio includes an increasing number of well-characterized antibodies for oncology research, produced in an ISO certified laboratory. MUbio’s partnered and proprietary R&D projects focus on the identification and validation of cancer biomarkers, development of lung cancer diagnostic kits & research and development of a lung cancer vaccine. | Health Technology |
| NovoVacs BV | |
| Dutch Vaccines Group | |
| LifetecZONe |
- Borsa valori
- Insiders
- Stefan van den Eijnde
